Ann: CannEpil Authorised to Commence Australian Sales, page-51

This is very good news in any measure
Excerpt -----
This is a major milestone which represents the Company’s progress towards becoming a world-leading Bio-Pharma company, with more than 10 years’ clinical experience and a leading Scientific Advisory Board in place.
It also signals the immediate commencement of commercial-scale production of CannEpilTM at MXC’s EU GMP certified facility in Slovenia, and the start of revenue generation from the Company’s core pharma activity.
The first batch of CannEpilTM is expected to be available for sale in Australia by December 2018, and will be distributed under the agreement with specialist Australian pharmaceutical distributor, HL Pharma
MGC Pharmaceuticals is working with a number of Australian based specialist doctors and neurologists, who will operate under the Ethics Committee approval in place and have applied to the TGA for specific approval to prescribe CannEpilTM to their patients who suffer from drug resistant epilepsy.

DYOR
FH